Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents
Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality. Tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) significantly worsens prognosis. We present four cases of male patients (average age 57) with HCC and TT extend...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1470374/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846128329947611136 |
|---|---|
| author | Yubin Hai Tingting Lin Guangyi Wang Xiaodong Sun Lan Wang Yuying Hai Saisai Chen Xiaoju Shi |
| author_facet | Yubin Hai Tingting Lin Guangyi Wang Xiaodong Sun Lan Wang Yuying Hai Saisai Chen Xiaoju Shi |
| author_sort | Yubin Hai |
| collection | DOAJ |
| description | Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality. Tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) significantly worsens prognosis. We present four cases of male patients (average age 57) with HCC and TT extending into the IVC/RA, treated at our center. All underwent hepatectomy and TT resection, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) administered post-operatively. Case 1 involved a 59-year-old male who had a right hepatectomy and TT resection in the IVC, followed by targeted therapy and immunotherapy, and is currently alive 74 months post-treatment. Case 2, a 48-year-old male, had a right hepatic lobectomy and TT resection in the IVC/RA, followed by liver transplantation 54 months postoperatively, with no recurrence. Case 3, a 66-year-old male, underwent a left hepatectomy and TT resection in the IVC, remaining disease-free 27 months postoperatively. Case 4, a 55-year-old male, received 15 cycles of combined targeted and immune therapy, followed by left hepatectomy and TT resection in the IVC/RA, with no recurrence 22 months postoperatively. Surgical resection combined with targeted and immunotherapy may enhance survival in advanced HCC patients with TT in the IVC/RA. Further studies are required to corroborate these findings. |
| format | Article |
| id | doaj-art-8c223d56e1a0403fa3d546cb45ed5bf7 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-8c223d56e1a0403fa3d546cb45ed5bf72024-12-11T05:10:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-12-011410.3389/fonc.2024.14703741470374Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agentsYubin Hai0Tingting Lin1Guangyi Wang2Xiaodong Sun3Lan Wang4Yuying Hai5Saisai Chen6Xiaoju Shi7Department of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Hepatobiliary and Pancreatic Surgery II, General Surgery Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, ChinaSchool of Stomatology, Jilin University, Changchun, ChinaDepartment of Neurology, Stroke Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, ChinaPrimary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality. Tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) significantly worsens prognosis. We present four cases of male patients (average age 57) with HCC and TT extending into the IVC/RA, treated at our center. All underwent hepatectomy and TT resection, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) administered post-operatively. Case 1 involved a 59-year-old male who had a right hepatectomy and TT resection in the IVC, followed by targeted therapy and immunotherapy, and is currently alive 74 months post-treatment. Case 2, a 48-year-old male, had a right hepatic lobectomy and TT resection in the IVC/RA, followed by liver transplantation 54 months postoperatively, with no recurrence. Case 3, a 66-year-old male, underwent a left hepatectomy and TT resection in the IVC, remaining disease-free 27 months postoperatively. Case 4, a 55-year-old male, received 15 cycles of combined targeted and immune therapy, followed by left hepatectomy and TT resection in the IVC/RA, with no recurrence 22 months postoperatively. Surgical resection combined with targeted and immunotherapy may enhance survival in advanced HCC patients with TT in the IVC/RA. Further studies are required to corroborate these findings.https://www.frontiersin.org/articles/10.3389/fonc.2024.1470374/fullhepatocellular carcinomatumor thrombushepatectomytargeted and immunotherapeutic drugscase report |
| spellingShingle | Yubin Hai Tingting Lin Guangyi Wang Xiaodong Sun Lan Wang Yuying Hai Saisai Chen Xiaoju Shi Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents Frontiers in Oncology hepatocellular carcinoma tumor thrombus hepatectomy targeted and immunotherapeutic drugs case report |
| title | Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents |
| title_full | Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents |
| title_fullStr | Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents |
| title_full_unstemmed | Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents |
| title_short | Case report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents |
| title_sort | case report combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents |
| topic | hepatocellular carcinoma tumor thrombus hepatectomy targeted and immunotherapeutic drugs case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1470374/full |
| work_keys_str_mv | AT yubinhai casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT tingtinglin casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT guangyiwang casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT xiaodongsun casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT lanwang casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT yuyinghai casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT saisaichen casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents AT xiaojushi casereportcombinationtherapyforhepatocellularcarcinomawithinferiorvenacavaorrightatrialtumorthrombusintheeraofcombinedtargetedandimmunotherapeuticagents |